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INTRODUCTION
Chronic hepatitis B virus (HBV) infects approximately 292 mil-
lion persons around the world and attributes to about half of the 
hepatocellular carcinoma (HCC) cases every year.1 HCC is a cancer 
with high mortality rate, with most cases detected at advanced 
stages.2 HCC surveillance remains indispensable to detect tumor 
at early stages in order to improve the prognosis of patients.3 
Chronic hepatitis B (CHB) patients with high serum HBV DNA lev-
els, elevated alanine aminotransferase (ALT) levels, advanced fi-
brosis and necroinflammation are at risk of developing HCC, 
hence are indicated for antiviral therapy.4-6 CHB patients received 
antiviral treatment have significantly lower risk of HCC and liver-
related mortality.7,8 On the other hand, patients who do not fulfil 
treatment criteria may also develop HCC.9,10 Thus, some untreated 
patients may have a significant risk of HCC development and thus 
benefit from antiviral treatment.
Advanced fibrosis and cirrhosis are the key risk factors of 
HCC.11,12 Liver biopsy examination was commonly used to assess 
liver fibrosis, yet its invasiveness and potential complications limit 
its generalizability.13 Liver stiffness measurement by transient elas-
tography is a non-invasive method to assess liver fibrosis, yet the 
measurement is limited by the availability of the machine. Instead, 
various serum test-based formulae have been developed to pre-
dict liver fibrosis with a reasonable accuracy. While some of these 
formulae (for example Enhanced Liver Fibrosis) require the mea-
surement of uncommon and expensive laboratory parameters in-
cluding aminoterminal propeptide of type III procollagen, hyal-
uronic acid and tissue inhibitor of matrix metalloproteinase type-
1.14 A few formulae comprised of common laboratory tests have 
been widely used. The most commonly used formulae include as-
partate aminotransferase to platelet ratio index (APRI), fibrosis-4 
(FIB-4) index, and Forns index.15 These serum fibrosis scores that 
reflected the severity of liver fibrosis could be useful to define the 
HCC risk of CHB patients, in particulars in those remained un-
treated.16,17 Existing HCC risk scores for untreated CHB patients in-
cluding the Chinese University of Hong Kong-HCC (CU-HCC) 
score, the guide with age, gender, HBV DNA, core promoter mu-
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tations and cirrhosis-HCC (GAG-HCC) score (without core promot-
er mutation), and the risk estimation for HCC in CHB (REACH-B) 
score rely heavily on clinical diagnosis of cirrhosis. The clinical di-
agnosis can however be subjective and vary among centers as liv-
er biopsy is not performed in most of the patients. Any misdiag-
nosis of liver cirrhosis will affect much on the classification of pa-
tients to different risk groups.
Based on the recommendations of American Association for the 
Study of Liver Diseases, an annual HCC risk of <0.2% is probably 
not cost-effective for HCC surveillance.4 In view of the huge num-
ber of CHB patients, a prediction score with high sensitivity to 
identify patients at very low risk of HCC would be pivotal to ap-
propriate allocation of healthcare resources for HCC surveillance. 
We may exempt these very-low-risk patients from HCC surveil-
lance and offer regular monitoring at primary care setting instead 
of secondary or tertiary centers.6 Appropriate resource allocation 
facilitates the elimination of HBV infection by 2030, a goal set by 
the World Health Organization (WHO).18 In the current study, we 
aimed to derive and validate a HCC risk score developed based on 
serum test formulae to exclude treatment-naïve CHB patients with 
low HCC risk.
PATIENTS AND METHODS
Study design and data source
The training cohort was a territory-wide retrospective cohort 
identified using data from the Clinical Data Analysis and Report-
ing System (CDARS) under the management of Hospital Authority, 
Hong Kong.19 Different territory-wide studies have been conduct-
ed using CDARS.20-23 The International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) coding system 
was used in CDARS. The use of ICD-9-CM codes in CDARS to 
identify hepatic events has been found 99% accurate when refer-
enced to clinical, laboratory, imaging and endoscopy results from 
the electronic medical records.24 The derived HCC risk score was 
externally validated in an independent cohort of CHB patients 
from Severance Hospital, Seoul, Korea.
Subjects
Consecutive adult CHB patients with positive hepatitis B surface 
antigen for 6 months and/or defined by the ICD-9-CM diagnosis 
codes between 2000 and 2017 in Hong Kong were identified. 
Those patients with serum HBV DNA and at least one of the se-
rum fibrosis scores (APRI, FIB-4, and Forns index) measured be-
tween January 2000 and June 2018 were included. Follow-up du-
ration were censored at the start date of first antiviral treatment 
for patients ever received antiviral treatment. HCC surveillance 
was done every 6 to 12 months by ultrasound and alpha-fetopro-
tein (AFP) testing under the Hospital Authority. APRI, FIB-4, and 
Forns index were calculated as described (Supplementary Table 
1).15,25,26 We excluded the following patients: those co-infected 
with hepatitis C virus and/or hepatitis D virus based on ICD-9-CM 
diagnosis codes, viral and serological markers and/or use of anti-
viral therapy for hepatitis C; co-infected with human immunodefi-
ciency virus based on ICD-9-CM diagnosis codes and/or use of 
antiviral therapy for human immunodeficiency virus; had other co-
existing autoimmune and metabolic liver diseases based on ICD-
9-CM diagnosis codes; had cancer including HCC and/or liver 
transplantation before or within the first 6 months after baseline 
date; follow-up duration less than 6 months; received rituximab 
and any chemotherapeutic agents (Supplementary Tables 1, 2). 
We also excluded patients with ICD-9-CM diagnosis codes of 
acute hepatitis B and/or positive immunoglobulin M to hepatitis B 
core antigen unless it was more than 6 months apart from a posi-
tive hepatitis B surface antigen result, patients with Child-Pugh 
class B or C or had any hepatic events before baseline. For valida-
tion cohort, CHB patients identified in 2000–2017 with available 
HBV DNA results in Severance Hospital, Seoul, Korea were includ-
ed. We excluded patients age younger than 18 years; develop 
HCC before or within first 6 months after baseline; follow-up less 
than 6 months; without available serum fibrosis scores at base-
line; with Child Pugh B or C and/or had any hepatic events before 
baseline.
Patients were followed until diagnosis of HCC, death, liver 
transplantation, starting antiviral treatment, last follow-up date 
(December 31, 2018), or up to 5 years of follow-up, whichever 
came first. The study protocol was approved by the Joint Chinese 
University of Hong Kong - New Territories East Cluster Clinical Re-
search Ethics Committee.
Data collection
Data of training cohort were retrieved from CDARS in January 
2019. Baseline date was set on the first serum HBV DNA assay. 
Demographic data including date of birth and gender were cap-
tured. At baseline, liver and renal biochemistries, hematological 
and virologic parameters were collected. Thereafter, serial liver 
502 http://www.e-cmh.orghttps://doi.org/10.3350/cmh.2020.0333
Volume_27  Number_3  July 2021
and renal biochemistries as well as HBV viral markers were col-
lected until the last follow-up date. We also retrieved data on 
other relevant diagnoses, procedures, concomitant drugs, labora-
tory parameters. Drug data of any antiviral treatment for CHB in-
cluding any approved nucleos(t)ide analogues, namely lamivudine, 
adefovir dipivoxil, entecavir, telbivudine, tenofovir disoproxil fu-
marate and tenofovir alafenamide, as well as (pegylated)-interfer-
on were also retrieved during the study period; patients’ follow-
up was censored at the time of first antiviral treatment. 
Definitions
The primary endpoint was HCC. HCC was identified based on 
diagnosis codes (155.0: HCC and 155.2: carcinoma of liver) or 
procedure codes for HCC treatment according to ICD-9-CM codes 
from CDARS. Liver cirrhosis was identified by ICD-9-CM diagnosis 
codes for cirrhosis and its related complications (Supplementary 
Table 2). Diabetes mellitus (DM) was defined by exposure to any 
anti-diabetic agents, and/or hemoglobin A1c ≥6.5% and/or fast-
ing plasma glucose ≥7.0 mmol/L in one measurement, and/or the 
ICD-9-CM diagnosis codes for DM.
Statistical analysis
Data were analyzed using SPSS version 25.0 (IBM Corp., Ar-
monk, NY, USA), and R software (4.0.0; R Foundation for Statisti-
cal Computing, Vienna, Austria). Continuous variables were ex-
pressed in mean±standard deviation or median (interquartile 
range [IQR]), as appropriate, while categorical variables were pre-
sented as frequency (percentage). Time to HCC diagnosis was de-
fined as the time from the baseline date to the date of first HCC 
diagnosis code, or the date of last follow-up if patients were still 
alive without HCC at the time of analysis. Kaplan-Meier analysis 
with log-rank test was used to estimate and compare the cumula-
tive risks of development of HCC in different groups of patients. 
Cox proportional hazards model was performed to determine the 
relationship of clinical characteristics of HBV DNA level, gender, 
age, serum bilirubin level, FIB-4 index and serum hepatitis e anti-
gen (HBeAg) status with the development of HCC. Missing values 
were excluded from the analysis. A simple HCC risk score was de-
rived by significant variables obtained from backward stepwise 
multivariable analysis with P<0.05. The score was the weighted 
sum of those variables of which the weights were defined as the 
Figure 1. The selection of patients in the training cohort and validation cohort. CHB, chronic hepatitis B; HBV, hepatitis B virus; HCC, hepatocellular car-
cinoma; AST, aspartate amionotransferase; PLT, platelet; ALT, alanine aminotransferase; GGT, gamma-glutaryl transpeptidase; NA, nucleos(t)ide ana-
logues.
74,856 Without available HBV DNA results
2,525  Developed HCC before or within first  
6 months after baseline
5,515 Developed other cancers before or at baseline
29,760  Missing results of serum test formula (AST,  
PLT, ALT, GGT, cholesterol) or results out of 
1 year from baseline
5,951 Started NA before or at baseline
800 Developed HCC at or after NA started
538 Follow-up duration less than 6 months
35 Younger than 18 years old
122  Child-Pugh class B and C
106 Hepatic events before baseline
96 Younger than 18 years old
1,661  Developed HCC before or within first 
6 months after baseline
224 Developed HCC at or after NA started
141 Without last follow up date
1,442 Follow up duration less than 6 months
592  Missing results of serum test formula (AST, 
PLT, ALT, GGT, cholesterol) or results out of 
1 year from baseline
45 Child-Pugh score calss B and C
73 Hepatic events before baseline
All CHB patients available
in Hong Kong health care
system in 2000–2017 after
exclusion
(n=135,395)
CHB patients wih HBV DNA
(n=15,187)
(training cohort)
Untreated CHB patients with
available HBV DNA
(n=8,559)
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quotient (rounded to nearest integer) of corresponding estimated 
coefficient from a Cox regression analysis divided by the smallest 
chi-square coefficient.11
The performance of serum fibrosis scores and the HCC risk score 
was assessed by area under the time-dependent receiver operat-
ing characteristic curve (AUROC).27 The 95% confidence interval 
(CI) for the comparison of two ROC curves was computed by 
bootstrap sampling of 1,000 samples. Diagnostic accuracy of the 
suggested cutoff values was assessed by sensitivity, specificity, 
positive predictive value, and negative predictive value (NPV) with 
95% CI. Youden’s index was used to select the best cutoff value. 
High sensitivity and NPV were used to further select the cutoff 
values with comparable Youden’s index to exclude patients with 
low HCC risk. All statistical tests were two-sided. P<0.05 was 
taken as statistically significant.
RESULTS
Patients characteristics
We identified in total 135,395 CHB patients in the public 
healthcare system in 2000–2017.28 There were 60,539 CHB pa-
tients with available HBV DNA results at baseline. After excluding 
patients fulfilling the exclusion criteria, the final number of treat-
ment-naïve CHB patients included in the training cohort was 
15,187. We identified 8,559 untreated CHB patients with available 
HBV DNA measurement in the validation cohort, 4,286 patients 
were finally analyzed after exclusion (Fig. 1).
During a mean follow-up of 52 months, 180 patients developed 
HCC in the training cohort. We compared the characteristics of 
patients developed HCC and without HCC. Patients who devel-
Table 1. Clinical characteristics of patients in the training and validation cohorts











Male 133 (73.9) 8,220 (54.8) <0.001 39 (83.0) 2,249 (53.1) <0.001
Age (years) 61.4±11.4 51.8±13.6 <0.001 58.0±11.9 48.4±12.6 <0.001
Age <50 years 24 (13.3) 6,295 (41.9) <0.001 10 (21.3) 2,228 (51.6) <0.001
Albumin (g/L) 38.1±5.6 41.6±4.9 <0.001 39.5±5.3 42.8±4.7 <0.001
Bilirubin (µmol/L) 14.1 (9.2–19.1) 11.0 (8.0–15.8) <0.001 13.7 (10.3–18.8) 12.0 (10.3–17.1) 0.964
ALT (IU/L) 46.0 (31.0–72.3) 37.0 (22.0–73.0) 0.001 26.0 (17.0–39.0) 24.0 (16.0–42.0) 0.678
AST (U/L) 33.1 (24.0–52.2) 30.0 (23.0–49.0) 0.081 30.0 (24.0–53.0) 24.0 (19.0–36.0) 0.001
Platelet (×109/L) 161.3±68.2 208.5±68.2 <0.001 155.1±63.2 201.2±68.3 <0.001
GGT (U/L) 70.2 (37.0–164.5) 29.0 (19.0–58.0) <0.001 56.5 (24.0–100.5) 25.0 (16.0–46.0) 0.001
Cholesterol (mmol/L) 4.6±1.2 4.8±1.1 0.002 4.2±1.0 4.7±1.0 0.002
Positive HBeAg 28 (18.8) 2,403 (17.7) 0.738 5 (13.2) 786 (23.3) 0.140
HBV DNA (log10 IU/mL) 5.0±1.8 4.4±2.1 <0.001 3.1±1.7 3.5±2.1 0.015
HBV DNA >2,000 IU/mL 138 (76.7) 8,711 (58.0) <0.001 11 (23.4) 1,374 (32.4) 0.189
Cirrhosis 56 (31.1) 765 (5.1) <0.001 37 (78.7) 916 (21.6) <0.001
APRI 0.7 (0.5–1.2) 0.4 (0.3–0.7) <0.001 0.5 (0.4–0.9) 0.3 (0.2–0.6) <0.001
FIB-4 index 2.5 (1.6–4.4) 1.3 (0.9–2.1) <0.001 2.4 (1.6–4.1) 1.3 (0.8–2.0) <0.001
FIB-4 >3.25 54 (38.6) 1,611 (12.5) <0.001 18 (38.3) 471 (11.1) <0.001
Forns index 7.4±2.0 5.6±2.0 <0.001 6.8±2.1 4.8±2.1 <0.001
Advanced fibrosis (%), APRI 
>2/FIB-4 >3.25/Forns  
index >8.4
70 (38.9) 2,087 (13.9) <0.001 20 (42.6) 537 (12.7) <0.001
Follow-up duration (months) 48.9±34.8 68.3±28.7 <0.001 46.0±32.0 49.5±33.6 0.477
Values are presented as mean±standard deviation, median (interquartile range), or number (%).
HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; AST, aspartate amionotransferase; GGT, gamma-glutaryl transpeptidase; HBeAg, hepatitis B e 
antigen; HBV, hepatitis B virus; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4.
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oped HCC were older (61.4±11.4 vs. 51.8±13.6 years), and more 
likely to be male (73.9% vs. 54.8%) than patients without HCC. 
More patients of non-HCC group were younger than 50 years 
(41.9%). For liver biochemistries, patients who developed HCC 
had lower albumin level (38.1±5.6 vs. 41.6±4.9 g/L), platelet 
count (161.3±68.2 vs. 208.5±68.2×109/L), cholesterol level 
(4.6±1.2 vs. 4.8±1.1 mmol/L) and higher total bilirubin (14.1 [IQR, 
9.2–19.1] vs. 11.0 [IQR, 8.0–15.8] µmol/L), ALT (46.0 [IQR, 31.0–
72.3] vs. 37.0 [IQR, 22.0–73.0] IU/L), gamma-glutaryl transpepti-
dase (GGT; 70.2 [IQR, 37.0–164.5] vs. 29.0 [IQR, 19.0–58.0] U/L) 
than patients without HCC. Patients with HCC had cirrhosis 
(31.1% vs. 5.1%) and higher HBV DNA level (5.0±1.8 vs. 4.4±2.1 
log10 IU/mL). Their serum fibrosis scores of APRI (0.7 [IQR, 0.5–
1.2] vs. 0.4 [IQR, 0.3–0.7]), FIB-4 index (2.5 [IQR, 1.6–4.4] vs. 1.3 
[IQR, 0.9–2.1]), and Forns index (7.4±2.0 vs. 5.6±2.0) were all 
higher than those of non-HCC patients (Table 1). The AFP levels in 
patients developed HCC was significantly higher than patients did 
not develop HCC (6.1 [IQR, 3.3–11.6] vs. 3.1 [IQR, 2.2–4.9] ng/mL, 
P<0.001). Patients developed HCC had more proportion of DM 
than patients did not develop HCC (37.2% vs. 18.6%, P<0.001).
In the validation cohort, 47 patients developed HCC during a 
mean follow-up of 50 months. Compared with the training co-
hort, patients in the validation cohort were younger (48.5±12.6 
vs. 52.0±13.6) and had more patients with cirrhosis (22.2% vs. 
5.4%). Patients had similar albumin level, platelet count, APRI and 
FIB-4 index in both of the training and validation cohorts (Table 1).
Predictors of HCC
We performed univariate and multivariable analysis for APRI, 
FIB-4 index separately. Forns index is not generally used in clinical 
assessment of Hong Kong and there were more than half of miss-
ing values in our cohort. So, we did not select Forns index to devel-
op the new score. APRI >2 was not associated with HCC develop-
ment in both univariate and multivariable analysis (Supplementary 
Table 3). FIB-4 >3.25, male gender, age older than 50 years old, 
high total bilirubin (bilirubin >18 µmol/L), low platelet (platelet 
<150×109/L), high HBV DNA level (HBV DNA >2,000 IU/mL) and 
DM were correlated with HCC development by univariate analy-
sis.29 There were 2,155 patients (14.2%) without FIB-4 index and 
these patients were excluded from the Cox proportional hazards 
model. Male gender, age older than 50, high HBV DNA level and 
high FIB-4 could predict HCC development significantly in multi-
variable analysis (Table 2).
Derivation of HCC prediction score
FIB-4 score combined with gender, age and HBV DNA level 
which were significant in the multivariable analysis comprised the 
new HCC prediction score named Liang score and ranged from 0 
to 22 (Table 3).
We listed out several potential cutoff values and calculated the 
diagnostic accuracy of these values (Table 4). Among these val-
Table 2. Univariate and multivariable analysis of Cox proportional hazards models on risk factors associated with hepatocellular carcinoma in the train-





HR 95% CI P-value χ2 score Adjusted HR 95% CI P-value
Male sex 8,353 (55.0) 1.96 1.31–2.95 0.001 6.71 1.96 1.18–3.26 0.010
Age (years)
<50 6,319 (41.6) 1 1
50–60 4,833 (31.8) 5.64 2.83–11.23 <0.001 15.89 4.93 2.25–10.79 <0.001
≥60 4,035 (26.6) 10.61 5.44–20.71 <0.001 21.32 6.51 2.94–14.43 <0.001
Bilirubin >18 µmol/L 2,537 (16.7) 2.00 1.33–3.01 0.001
Platelet <150×109/L 2,654 (17.5) 3.40 2.34–4.95 <0.001
HBV DNA >2,000 IU/mL 8,849 (58.3) 2.07 1.36–3.15 0.001 4.26 1.77 1.03–3.03 0.039
FIB-4 >3.25 1,667 (11.0) 4.46 2.89–6.88 <0.001 15.16 2.70 1.64–4.45 <0.001
HBeAg (+) 2,431 (16.0) 0.86 0.49–1.49 0.586
DM 2,865 (18.9) 3.14 2.16–4.58 <0.001
Values are presented as number (%) unless otherwise indicated.
HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; FIB-4, fibrosis-4; HBeAg, hepatitis B e antigen; DM, diabetes mellitus.
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ues, cutoff value of 10 had the highest Youden’s index of 0.406, 
followed by the cutoff value of 9 with Youden’s index of 0.391. As 
the corresponding sensitivity and NPV of 9 were 83.7% (95% CI, 
73.9–90.5%) and 99.8% (95% CI, 99.7–99.9%), which were 
higher than those of the cutoff value of 10 (sensitivity, 74.4%; 
specificity, 99.7%), we finally selected 9 as the cutoff value of the 
Liang score. By using the cutoff value of 9, patients were divided 
into two groups: low-risk group (7,191 patients) with Liang score 
≤9 and high-risk group (5,841 patients) with Liang score >9. The 
corresponding number of patients developed HCC were 14 
(0.19%) and 72 (1.12%) in the low- and high-risk groups at 
5 years’ follow-up duration. The cumulative incidence of HCC was 
significantly different between low- and high-risk patients by Ka-
plan-Meier analysis (log-rank test, P<0.001). The annual HCC in-
cidences of low-risk group were less than 0.2%, which is the 
threshold of offering cost-effective HCC surveillance (Fig. 2A).
We compared the performance of Liang score in patients never 
receive antiviral treatment and patients received antiviral treat-
ment and censored at the start date of the treatment (Supplemen-
tary Table 4). The sensitivity (81.82% vs. 84.38%) and NPV 
(99.91% vs. 99.61%) were similar between these two groups.
External validation of HCC prediction score
In the validation cohort, there were 2,686 patients (62.8%) 
classified as low-risk groups, among which three patients (0.11%) 
developed HCC. The corresponding sensitivity and NPV of cutoff 
of 9 were 90.0% (95% CI, 72.3–97.4%) and 99.9% (95% CI, 
99.6–99.97%), respectively (Table 5). The cumulative incidence of 
HCC in low-risk patients was significantly lower than that in high-
risk patients (log-rank test, P<0.001), and was less than 0.2% per 
year (Fig. 2B). Liang score performed well in patients with or 
without cirrhosis and subgroups of patients with different AFP 
levels (Supplementary Tables 5, 6).
Comparison with existing HCC prediction scores
We compared the performance of Liang score with other HCC 
prediction scores which were developed in treatment-naïve CHB 
patients: CU-HCC score, GAG-HCC score and REACH-B score in 
the validation cohort. We selected conventionally used cutoff val-
ues of 5, 100 and 8 for CU-HCC score, GAG-HCC score and REACH-B 















Total 0 to 22
HBV, hepatitis B virus; FIB-4, fibrosis-4.
Table 4. Diagnostic accuracy of Liang score (follow-up duration: 5 years)
Cut off value
2 3 5 7 9 10 12
Sensitivity 97.7 (91.1–99.6) 95.3 (87.9–98.5) 90.7 (82.0–95.6) 89.5 (80.6–94.8) 83.7 (73.9–90.5) 74.4 (63.7–82.9) 55.8 (44.7–66.4)
Specificity 19.5 (18.8–20.2) 28.8 (28.0–29.6) 42.0 (41.2–42.9) 48.2 (47.3–49.0) 55.4 (54.6–56.3) 66.2 (65.4–67.0) 80.2 (79.5–80.9)
PPV 0.8 (0.6–1.0) 0.9 (0.7–1.1) 1.0 (0.8–1.3) 1.1 (0.9–1.4) 1.2 (1.0–1.6) 1.4 (1.1–1.8) 1.8 (1.4–2.5)
NPV 99.9 (99.7–99.98) 99.9 (99.7–99.97) 99.9 (99.7–99.9) 99.9 (99.7–99.9) 99.8 (99.7–99.9) 99.7 (99.6–99.8) 99.6 (99.5–99.7)
No. of HCC 
predicted
84/86 82/86 78/86 77/86 72/86 64/86 48/86
No. of low-
risk patients
2,522/13,032 3,730/13,032 5,451/13,032 6,245/13,032 7,191/13,032 8,592/13,032 10,422/13,032
Values are presented as percentage (95% confidence interval) or number.
PPV, positive predictive value; NPV, negative predictive value; HCC, hepatocellular carcinoma.
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score, respectively.11,30,31 The sensitivity and NPV results were 
83.3% and 99.8% for CU-HCC score; 70.0% and 99.8% for 
GAG-HCC score and 65.2% and 99.6% for REACH-B score, which 
were all lower than those of Liang score (90.0% and 99.9%). The 
number of low-risk patients defined by CU-HCC score, GAG-HCC 
score and REACH-B score were 2,403, 3,639, and 1,933 with HCC 
incidence of 0.21%, 0.25%, and 0.41%, respectively (Table 5). 
Time-dependent AUROC was used to compare the predictive abil-
ity of Liang score with other HCC prediction scores. The time-de-
pendent AUROC of Liang score was 0.79 (95% CI, 0.70–0.89) 
which was not significantly different to those of CU-HCC score 
(0.82; 95% CI, 0.75–0.89; P=0.434) and GAG-HCC score (0.83; 
95% CI, 0.74–0.91; P=0.342). The time-dependent AUROC of Li-
ang score was significantly higher than that of REACH-B score 
(0.61; 95% CI, 0.53–0.70; P<0.001; Supplementary Fig. 1).
Patients who may be exempted from HCC 
surveillance
Patients with Liang score of 9 or lower may be exempted from 
HCC surveillance which include the following groups: female pa-
tients younger than 50; female patients age between 50 and 60 
with low FIB-4 score or male patients younger than 50 with low 
FIB-4 score (Table 3). The corresponding annual HCC incidences 
of these groups were all less than 0.2% in the training cohort.
DISCUSSION
We aimed to derive and validate a HCC risk score based on se-
rum fibrosis scores to identify a group of patients with very low 
risk of HCC in treatment-naïve CHB patients. The newly developed 
Figure 2. Cumulative incidence of HCC in the low- and high-risk of patients defined by Liang score in the (A) training cohort and (B) validation cohort 























0 12 24 36 48 60
Follow-up duration (months)
No. at risk
Liang score >9 5,841 5,738 5,394 4,652 4,025 3,406
Liang score ≤9 7,191 7,180 6,978 6,112 5,562 5,055
HCC incidence
(% per year)
- 0.04 0.07 0.01 0.03 0.05
 Liang score >9























0 12 24 36 48 60
Follow-up duration (months)
No. at risk
Liang score >9 1,594 1,458 1,208 930 728 547
Liang score ≤9 2,686 2,371 1,936 1,465 1,137 883
HCC incidence
(% per year)
- 0 0 0.10 0.07 0
 Liang score >9
 Liang score ≤9
P<0.001
Table 5. Diagnostic accuracy of Liang score and other HCC prediction scores in the validation cohort (follow-up duration: 5 years)
Liang score cutoff: 9 CU-HCC score cutoff: 5 GAG-HCC score cutoff: 100 REACH-B score cutoff: 8
Sensitivity 90.0 (72.3–97.4) 83.3 (64.5–93.7) 70.0 (50.4–84.6) 65.2 (42.8–82.8)
Specificity 63.1 (61.7–64.6) 57.2 (55.7–58.7) 85.3 (84.2–86.3) 57.0 (55.3–58.6)
PPV 1.7 (1.1–2.5) 1.4 (0.9–2.1) 3.2 (2.1–5.0) 1.0 (0.6–1.7)
NPV 99.9 (99.6–99.97) 99.8 (99.5–99.9) 99.8 (99.5–99.9) 99.6 (99.2–99.8)
No. of HCC predicted 27/30 25/30 21/30 15/23
No. of patients below cutoff 2,686/4,280 2,403/4,219 3,639/4,286 1,933/3,402
Values are presented as percentage (95% confidence interval) or number.
CU-HCC, the Chinese University of Hong Kong-HCC; GAG-HCC, the guide with age, gender, HBV DNA, core promoter mutations and cirrhosis-HCC; REACH-B, 
the risk estimation for HCC in CHB; PPV, positive predictive value; NPV, negative predictive value; HCC, hepatocellular carcinoma.
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Liang score was composed of gender, age, HBV DNA and FIB-4 
index, which was accurate and reproducible to exclude HCC. By 
using the cutoff value of 9, around 50% of patients were classi-
fied as very low risk of HCC (annual incidence <0.2%), so that 
HCC surveillance would be exempted. As Liang score was com-
posed of common clinical and laboratory parameters, it would be 
applicable in most clinic settings. This score would contribute to 
the WHO’s hepatitis elimination advocacy by better resource allo-
cation.
The current international guidelines recommend that adult CHB 
patients with cirrhosis should undergo regular HCC surveillance.32 
However, the recommendations in non-cirrhotic CHB patients are 
not as clear. For example, the American guidelines recommend 
screening in male CHB patients above 40 years old, which refers 
to majority of the male patients as adults of early 30s or younger 
are mostly vaccinated in our region. With this novel Liang score, 
the following types of CHB patients would be classified as high-
risk with a cutoff value of 9: 1) female patients older than 60 
years; 2) female patients with age between 50 and 60 years and 
FIB-4 >3.25; 3) male patients older than 50 years; and 4) male 
patients younger than 50 years with FIB-4 >3.25. The corre-
sponding cumulative HCC incidence of these groups at 5 years’ 
follow-up were 1.5%, 1.8%, 1.7%, and 2.2% in the training co-
hort. The annual HCC incidences were all higher than 0.2% that 
indicates the possible need of HCC surveillance. These few groups 
of patients account for 45% in the training cohort and 37% in the 
validation cohort.
A few existing HCC prediction scores such as CU-HCC score and 
GAG-HCC score include clinical cirrhosis as a key component with 
strong weight; yet cirrhosis may not be diagnosed accurately by 
ultrasonography.33 We substituted clinical cirrhosis with FIB-4 
score, a more objective serum fibrosis score, and then built the Li-
ang score, which is highly applicable and reproducible. By using 
the cutoff value of 9, Liang score had the highest sensitivity 
(90.0%) and NPV (99.9%) compared with CU-HCC score, GAG-
HCC score and REACH-B score which were developed in treat-
ment-naïve patients. Therefore, Liang score was accurate to rule 
out HCC in low-risk patients and it worked excellently among cur-
rent HCC prediction scores in treatment-naïve CHB patients with-
out the necessity of accurate diagnosis of liver cirrhosis.
Our study had some strengths. First, Liang score is composed of 
common clinical and laboratory parameters such that it is applica-
ble in most clinic settings. Aiming a highly sensitive cutoff achiev-
ing very high NPV can identify very-low-risk patients who would 
not need HCC surveillance in the near future. Second, Liang score 
is accuracy to exclude low HCC risk patients without the diagnosis 
of cirrhosis and not affected by operators compared with ultra-
sound, which is relatively inaccurate to diagnose cirrhosis for HCC 
surveillance. Third, Liang score was derived in the cohort of Hong 
Kong patients and externally validated in the Korean cohort. Both 
of the cohorts had respectable sample size and the results sup-
ported that Liang score is accurate and generally applicable in dif-
ferent ethnic groups in Asia.
There were also few limitations of our study. First, Liang score 
was developed in Hong Kong cohort and validated in Korean co-
hort, such that its accuracy in Caucasians is uncertain. Further 
studies based on patients of other ethnic groups are needed. Sec-
ond, our study was based on treatment-naïve CHB patients. Until 
further data are available, the findings of our study cannot be ex-
trapolated to patients on antiviral treatment. Third, we did not 
explore the role of the HBV genotypes as it is not a routine test in 
Hong Kong and we cannot show the size and stage of HCC. The 
common HBV genotypes in Hong Kong include genotype B and C; 
whereas it is exclusively genotype C in Korea.34 Genotype C HBV 
is associated with an increased risk of HCC.34,35 Fourth, the HCC 
incidence of our cohort was only 1.2% in more than 5 years, as it 
was a treatment-naïve cohort. Such low incidence further support 
the urgent need of a highly sensitive score like Liang score which 
saves the resources of HCC surveillance in around 50% of such 
patients. Fifth, there were many missing HBV DNA results in our 
cohort as the test was available widely in Hong Kong from the 
year of 2012. Many old patients may did not receive the test. 
Sixth, we did not collect the presence of non-alcoholic fatty liver 
disease and other metabolic factors like insulin resistance and 
obesity which may affect the risk of HCC at long term. Finally, the 
diagnosis of cirrhosis in our study most based on the ultrasonog-
raphy, which may be not accurate and influence the reliability of 
CU-HCC score and GAG-HCC score.
In conclusion, Liang score, composed of common parameters 
including gender, age, HBV DNA and FIB-4 index, is accurate to 
exclude HCC in treatment-naïve CHB patients. Liang score identi-
fies patients at very low risk of HCC so that HCC surveillance can 
be exempted. Further studies are needed to validate the Liang 
score in prospective cohorts.
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